<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63835">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01993537</url>
  </required_header>
  <id_info>
    <org_study_id>20120585</org_study_id>
    <nct_id>NCT01993537</nct_id>
  </id_info>
  <brief_title>The Role of Vitamin D in the Pathophysiology of Chronic Failure</brief_title>
  <official_title>The Role of Vitamin D in the Pathophysiology of Chronic Failure: Insight in to Mechanisms of Action and Implications for Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ottawa Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ottawa Heart Institute</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will undergo at baseline and regular intervals:

        -  clinically indicated bloodwork/urine and echocardiogram testing

        -  biomarker studies

      Upon enrolment in the study patients will be divided into 4 groups normal, mildly deficient
      and severely deficient. Normal and mild vitamin D levels will receive no treatment while
      severe Vitamin D deficiency will be randomized (50/50) to receive no treatment or vitamin D
      treatment. They will be seen in the heart failure clinic every 6 months. The patients will
      be followed for 26 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inclusion criteria for the study is:

        -  an EF ≤40% within the last 12 months before recruitment

        -  established diagnosis of heart failure

        -  &gt;18 years of age

        -  patients will vitamin d levels of sufficient, mild deficiency and severe deficiency

      The exclusion criteria is:

        -  hypercalcemia

        -  known hypersensitivity to Vitamin D

        -  patient unwilling to comply with study requirements

        -  any other disease other than heart failure that can alter the patients quality of life
           over a period of 6 months

        -  women of child bearing potential

        -  a patient currently taking vitamin d

        -  severe renal impairment estimated glomerular filtration rate (eGFR) &lt;30
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>prevalence of Vitamin D deficiency  amongst chronic heart failure patients at the University of Ottawa Heart Institute</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome for the study is to identify the prevalence of Vitamin D deficiency amongst chronic heart failure patients followed at the University of Ottawa Heart Institute. This will be done analyzing the Vitamin D blood levels at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that Vitamin D deficiency is associated with poor outcome and that Vitamin D supplementation can be of clinical benefit</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical endpoints of: hospitalizations for worsening congestive heart failure, death will be compared for severe Vitamin D deficient patients receiving Vitamin D supplementation vs severe Vitamin D deficient patients receiving no intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sufficeint</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Insufficiency</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Deficiency no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Deficiency - Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Severe Deficiency - Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an ejection fraction (EF) ≤40% within the last 12 months before recruitment

          -  established diagnosis of heart failure

          -  &gt;18 years of age

          -  patients with Vitamin D levels of sufficient, mild deficiency and severe deficiency

        Exclusion Criteria:

          -  hypercalcemia

          -  known hypersensitivity to Vitamin D

          -  patient unwilling to comply with study requirements

          -  any other disease other than heart failure that can alter the patients quality of
             life over a period of 6 months

          -  women of child bearing potential

          -  a patient currently taking vitamin d

          -  severe renal impairment eGFR &lt;30
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haissam Haddad</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Ottawa Heart Insitute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JoAnn Donaldson</last_name>
    <phone>613-761-4296</phone>
    <email>jdonaldson@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Baker</last_name>
    <phone>613-761-5120</phone>
    <email>abaker@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnn Donaldson</last_name>
      <phone>613-761-4296</phone>
      <email>jdonaldson@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ann Baker</last_name>
      <phone>613-761-5120</phone>
      <email>abaker@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Haissam Haddad</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Girish Dwivedi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Pourdjabbar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Mielniczuk</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Burwash</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>marcel Ruzicka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ottawa Heart Institute</investigator_affiliation>
    <investigator_full_name>Haissam Haddad</investigator_full_name>
    <investigator_title>Director Heart Failure Program, Medical Director Heart Transplant Program</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
